Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling
Year: 2018
Type: article
Institutions: Brigham and Women's Hospital, Harvard University
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: American Heart Association, Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Bayer, GlaxoSmithKline, Sanofi, American College of Cardiology Foundation, Biogen, Alnylam Pharmaceuticals, Cleveland Clinic, Boston Scientific Corporation, Boston VA Research Institute, Regeneron Pharmaceuticals, Ironwood Pharmaceuticals, Incorporated, Amarin Corporation, Medicines Company, Kowa Company, Luitpold Pharmaceuticals, Singulex, Regado Biosciences, Belvoir Media Group, European Commission, Eisai, Novo Nordisk, Vifor Pharma, Idorsia Pharmaceuticals, National Institutes of Health, St. Jude Medical, Relypsa, National Heart, Lung, and Blood Institute, Duke Clinical Research Institute, Daiichi Sankyo Europe
OpenAlex ID: W2900236147
